April 14, 2021
BioAge Labs announces an exclusive agreement with Amgen to develop and commercialize an APJ agonist aimed at ameliorating muscle aging.
BioAge Labs raises a $90,000,000 series C round from AME Cloud Ventures, Aarp Foundation, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures, Kaiser Foundation Hospitals, Pear, Phi-X Capital and Redpoint Ventures.
BioAge Labs raises a $23,000,000 series B round from AME Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Felicis Ventures, Khosla Ventures, Pear and Redpoint Ventures.
BioAge Labs raises a $10,900,000 series A round from AME Cloud Ventures, Andreessen Horowitz, Caffeinated Capital, Elad Gil, Felicis Ventures and Pear.
Funding round amount (USD)
Funding round date
Results per page:
Page 1 of 1
Documentaries, videos and podcasts
April 15, 2021
BGE-105 (formerly AMG 986) mimics the production of apelin, a peptide that has been found in animal studies to improve muscle regeneration and decrease mouse frailty.
Amirah Al Idrus
April 14, 2021
BioAge Labs is adding a third program to its pipeline. The new treatment, licensed from Amgen, is designed to combat muscle aging and could be useful in helping older people recover from surgery more quickly, decreasing muscle atrophy after a long hospital stay, or eventually, warding off frailty in older people.
April 6, 2021
Shanghai Stock Exchange listed biotech company HitGen Inc. ("HitGen") announced important research progress in a collaboration with BioAge Labs, Inc. ("BioAge"), a private biotechnology company developing targeted small molecules for the treatment of diseases of aging.
December 3, 2020
Check out some news happening today around the biopharma industry.